Rafivirumab
Rafivirumab is a monoclonal antibody designed for the treatment of cancer. It was developed by Eli Lilly and Company.
Mechanism of action[edit]
Rafivirumab works by inhibiting the vascular endothelial growth factor receptor 2 (VEGFR2), which is involved in the growth and development of new blood vessels. By blocking this receptor, rafivirumab can help to slow the growth of tumors.
Clinical trials[edit]
Rafivirumab has been studied in several clinical trials for various types of cancer, including colorectal cancer, lung cancer, and gastric cancer. However, the results have been mixed, and the drug is not currently approved for use in any country.
Side effects[edit]
Like all drugs, rafivirumab can cause side effects. The most common side effects reported in clinical trials include fatigue, diarrhea, and high blood pressure. In some cases, rafivirumab can also cause more serious side effects, such as bleeding, blood clots, and heart problems.
See also[edit]
References[edit]
<references />
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
